Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

Autor: Pérol, Maurice, Ciuleanu, Tudor-Eliade, Arrieta, Oscar, Prabhash, Kumar, Syrigos, Konstantinos N., Goksel, Tuncay, Park, Keunchil, Kowalyszyn, Ruben Dario, Pikiel, Joanna, Lewanski, Conrad R., Thomas, Michael, Dakhil, Shaker, Kim, Joo-Hang, Karaseva, Nina, Yurasov, Sergey, Zimmermann, Annamaria, Lee, Pablo, Carter, Gebra Cuyun, Reck, Martin, Cappuzzo, Federico, Garon, Edward B.
Zdroj: In Lung Cancer March 2016 93:95-103
Databáze: ScienceDirect
Externí odkaz: